ArticleFrontiers in genetics2025
Next-generation sequencing of mitochondrial DNA reveals pathogenic variants and protective haplogroup D4 in esophageal cancer.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The germline variations in the mitochondrial genome of esophageal cancer (EC) remain uncertain. Our study aimed to explore the distribution and pathogenicity of mitochondrial genome variations in EC, as well as to identify haplogroups associated with the development of EC. Methods: We performed next-generation sequencing of the mitochondrial genomes from peripheral blood samples of 146 EC patients and 120 healthy controls. Variant annotation was performed using MitoMap, while pathogenicity prediction was conducted through tools such as MitoTip, SIFT, and PolyPhen2. Moreover, haplogroup classification was carried out using the Haplogrep3 platform. Results: A total of 1299 mitochondrial variants were identified among 146 EC patients, including 171 novel (previously unreported) mutations. Compared with the healthy control group, the EC cohort exhibited a higher frequency of variants in genes such as ND2, COX1, COX2, 12S rRNA, and 16S rRNA. Three tRNA mutations (7496_T>C, 5771_A>G, and 5613_T>A) were predicted to be potentially pathogenic. Within the protein-coding regions, 14 variants were classified as deleterious based on predictions from 13 independent bioinformatic algorithms. Notably, mitochondrial haplogroup D4 was significantly associated with a decreased risk of developing EC. Furthermore, several mtDNA single-nucleotide polymorphisms (SNPs), including 302_A>AC, 1824_T>C, 1842_A>G, 3010_G>A, 8414_C>T, and 14668_C>T, showed significant associations with EC susceptibility. Conclusion: We found that the number of variations in multiple regions of the mitochondrial genome in the EC population was higher than that in the control group. Additionally, several potentially pathogenic variants were identified, and haplogroup D4 was suggested as a potentially protective haplogroup against the development of EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.